Pfizer and Valneva recently announced that they will collaborate on developing Valneva’s Lyme disease vaccine candidate VLA15, presently in Phase 2 clinical studies.
Valneva is eligible to receive a total of $308 million, including $130 million upfront, according to an April 30 news release.
Get the full story on our WTWH Media sister site R&D World.
Filed Under: Drug Discovery and Development, Infectious Disease
Tell Us What You Think!
You must be logged in to post a comment.